Sanofi Pasteur To File Quick Response To cGMP Violations At French Plant
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA untitled letter cites switch in pyrogen testing reagent and failure to thoroughly investigate problems and acknowledges Sanofi's commitment to corrections.
You may also be interested in...
As Sales Slip, Merck & Co. Plans 7,200 Job Cuts
Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.